ABI3BP

Across TCGA pan-cancer cohorts, ABI3BP mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ABI3BP data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ABI3BP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ABI3BP expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where ABI3BP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.845	0.611	.004	20	view →
LUAD	DFS	Tertile	II,III,IV	0.600	0.985	.007	10	view →
HNSC	OS	Tertile	II,III,IV	0.919	1.000	.010	9	view →
GBM	DFS	Median	All	0.660	0.831	.004	7	view →
CCRCC	OS	Median	All	0.953	0.835	.022	7	view →
LSCC	DFS	Tertile	II,III,IV	0.841	1.000	.034	4	view →
UCEC	DFS	Quartile	II,III,IV	0.681	1.000	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ABI3BP–PDAC (DFS)

Open the PDAC breakdown →